AJU IB Investment Company’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-12,437
| Closed | -$421K | – | 7 |
|
|
2025
Q4 | $421K | Hold |
12,437
| – | – | 1.85% | 6 |
|
|
2025
Q3 | $321K | Hold |
12,437
| – | – | 0.28% | 6 |
|
|
2025
Q2 | $99.5K | Sell |
12,437
-1
| -0% | -$8 | 0.11% | 8 |
|
|
2025
Q1 | $121K | Hold |
12,438
| – | – | 0.14% | 7 |
|
|
2024
Q4 | $157K | Buy |
+12,438
| New | +$158K | 0.15% | 8 |
|
|
2022
Q3 | $2.39M | Hold |
12,438
| – | – | 4.1% | 5 |
|
|
2022
Q2 | $1.82M | Hold |
12,438
| – | – | 3.52% | 6 |
|
|
2022
Q1 | $2.19M | Hold |
12,438
| – | – | 3.38% | 6 |
|
|
2021
Q4 | $3.65M | Hold |
12,438
| – | – | 5.09% | 5 |
|
|
2021
Q3 | $3.09M | Hold |
12,438
| – | – | 1.99% | 6 |
|
|
2021
Q2 | $3.16M | Sell |
12,438
-1,125
| -8% | -$210K | 1.82% | 6 |
|
|
2021
Q1 | $2.41M | Hold |
13,563
| – | – | 0.91% | 7 |
|
|
2020
Q4 | $2.14M | Buy |
+13,563
| New | +$2.95M | 0.81% | 7 |
|
AJU IB Investment Company's RAPT Position: Q1 2026 in Review
AJU IB Investment Company sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 12,437 shares — an estimated $421K sold.
AJU IB Investment Company first reported a position in RAPT in Q4 2020 and held it in 13 quarters. The position peaked at $3.65M in Q4 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- AJU IB Investment Company reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- AJU IB Investment Company sold 12,437 RAPT Therapeutics shares in Q1 2026, an estimated $421K.
- AJU IB Investment Company first reported a position in RAPT Therapeutics in Q4 2020 and held it in 13 quarters.
- AJU IB Investment Company's RAPT Therapeutics position peaked at $3.65M in Q4 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on AJU IB Investment Company's 13F filing for Q1 2026, filed 8 May 2026.